Overview

Pulsed Field Ablation (PFA) Versus Anti-Arrhythmic Drug (AAD) Therapy as a First Line Treatment for Persistent Atrial Fibrillation

Status:
Recruiting

Trial end date:
2027-12-30

Target enrollment:

Participant gender:

Summary

The purpose of this study is to establish the safety and effectiveness of pulsed field ablation as a first-line ablation treatment for subjects with persistent atrial fibrillation as compared to subjects who received an initial treatment with anti-arrhythmic drugs.

Phase:

N/A

Details

Lead Sponsor:

Boston Scientific Corporation

Treatments:

Anti-Arrhythmia Agents
Dofetilide
Flecainide
Propafenone
Sotalol